SFM
CLDI icon

Spartan Fund Management’s Calidi Biotherapeutics CLDI Stock Holding History

Spartan Fund Management’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,104
Closed -$3.2M – 284
2023
Q2 		$3.2M Buy
2,104
+854
+68% +$1.06M 0.78% 51
2023
Q1 		$1.54M Hold
1,250
– – 0.72% 44
2022
Q4 		$1.53M Hold
1,250
– – 0.55% 62
2022
Q3 		$1.48M Buy
+1,250
New +$1.5M 0.45% 91

Other funds holding CLDI

MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SAMC
Spectrum Asset Management (California) Newport Beach, California $315M AUM 19.93% 1-Year Est. Return
RWI
Red Wave Investments Dillsburg, Pennsylvania $335M AUM 15.13% 1-Year Est. Return
DIM
Delta Investment Management San Francisco, California $559M AUM 19.86% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Spartan Fund Management's CLDI Position: Q3 2023 in Review

Spartan Fund Management sold out of Calidi Biotherapeutics (CLDI) in Q3 2023, closing a stake of 2,104 shares — an estimated $3.2M sold.

Spartan Fund Management first reported a position in CLDI in Q3 2022 and held it in 4 quarters. The position peaked at $3.2M in Q2 2023. 12 funds tracked by Wall St. Rank hold CLDI as of Q3 2023.

  • Spartan Fund Management reported no remaining Calidi Biotherapeutics position as of Q3 2023 after selling out during the quarter.
  • Spartan Fund Management sold 2,104 Calidi Biotherapeutics shares in Q3 2023, an estimated $3.2M.
  • Spartan Fund Management first reported a position in Calidi Biotherapeutics in Q3 2022 and held it in 4 quarters.
  • Spartan Fund Management's Calidi Biotherapeutics position peaked at $3.2M in Q2 2023.
  • 12 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q3 2023.

Based on Spartan Fund Management's 13F filing for Q3 2023, filed 23 Oct 2023.